In combination chemotherapy, HIF-1α inhibition may alleviate hypoxic microenvironments in pancreatic cancer, improving the delivery efficiency of chemotherapeutic agents like gemcitabine (3). The gene discussed is HIF1A; the disease is pancreatic neoplasm.